Pathology and molecular biology of gastrointestinal stromal tumors (GIST);Pathologie und Molekularbiologie gastrointestinaler Stromatumoren (GIST)

Radiologe

Volumn 49, Issue 12, 2009, Pages 1104-1108

  Schildhaus, H U ^a   Merkelbach Bruse, S ^a   Buttner R ^a   Wardelmann, E ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Gastrointestinal stromal tumors (GIST); KIT; Mutation status; PDGFR

Indexed keywords

ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; HUMANS; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 73649130220     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-009-1850-y     Document Type: Short Survey

References (40)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT) - gastrointestinal stromal tumors show phenotypic characteristics ofthe interstitial cells of Cajal. Am J Pathol 152: 1259-1269
2. 2. Hirota S, Isozaki K, Moriyama Y et al (1998) Gainof-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580 (Pubitemid 28067289)
3. Wardelmann E, Neidt I, Bierhoff E et al (2002) c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15: 125-136
4. Wardelmann E, Pauls K, Merkelbach-Bruse S et al. (2004) Gastrointestinale Stromatumoren mit PDGFRa-Mutationen treten bevorzugt im Magen auf und zeigen einen epitheloiden oder gemischten Phänotyp. Verh Dtsch Ges Pathol 88: 174-183
5. Bednar B, Mirejovsky P (1986) Histogenesis of benign pleomorphic mesenchymal tumors. Cesk Patol 22: 241-244
6. Liegl B, Hornick JL, Corless CL, Fletcher CD (2009) Monoclonal antibody DOG 1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33: 437-446
7. 7. Fletcher CD, Berman J, Corless CL (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465 (Pubitemid 34747864)
8. 8. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83 (Pubitemid 44692418)
9. Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39(10): 1411-1419
10. 10. Corless CL, Mc Greevey L, Haley A et al (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160: 1567-1572 (Pubitemid 34525636)
11. Rubin BR Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121
12. 12. Taniguchi M, Nishida T, Hirota S (1999) Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59: 4297-4300 (Pubitemid 29418746)
13. 13. Lasota J, Wozniak A, Sarlomo-Rikala M et al (2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 157: 1091-1095 (Pubitemid 30757930)
14. Lux ML, Rubin BP, Biase TL et al (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156: 791-795
15. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710
16. Hirota S, Ohashi A,NishidaTetal (2003) Gain-offunction mutations in platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 125: 660-667 (Pubitemid 37070684)
17. 17. Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M (2004) A great majority of GIST with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84: 874-883 (Pubitemid 38833247)
18. Medeiros F, Corless CL, Duensing A et al (2004) KIT negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28: 889-894
19. 19. Lasota J, Stachura J, Miettinen M (2006) GIST with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86: 94-100 (Pubitemid 43250972)
20. 20. Andersson LJ, Sjögren H, Meis-Kindblom JM et al (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160: 15-22 (Pubitemid 34052260)
21. Bachet JB, Hostein I, Le Cesne A et al (2009) Prognosis and predictive value of KIT exon 11 deletion in GIST. Br J Cancer 101: 7-11
22. Wardelmann E, Losen I, Hans V, et al. (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106: 887-895
23. Martin J, Poveda A, Llombart-Bosch A et al (2005) Deletions affecting codons 557-558 ofthe c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23: 6190-6198
24. 24. Lasota J, Dansonka-Mieszkowska A, Stachura T et al (2003) Gastrointestinal stromal tumors with internal tandem duplications in 3′end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16: 1257-1264 (Pubitemid 38018608)
25. Lasota J, Kopczynski J, Sarlomo-Rikala M (2003) KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34: 1306-1312
26. Antonescu C, Sommer G, Sarran L (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9: 3329-3337
27. Wardelmann E, HrychykA, Merkelbach-BruseS (2004) Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6: 197-204 (Pubitemid 39136646)
28. Heinrich MC, Corless CL, Demetri GD (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21: 4342-4349
29. Debiec-Rychter M, Dumez H, Judson I (2004) Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and Il studies ofthe EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689-695
30. Blanke C, Joensuu H, Demetri G (2004) Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. ASCO Annual Meeting 2004, abstract no. 2
31. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103 (Pubitemid 44275331)
32. Demetri GD, Desai J, Fletcher J et al (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). ASCO Annual Meeting 2004, abstract no. 3001
33. Ma Y, Zeng S, Metcalfe D, et al (2002) The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitory sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744
34. Debiec-Rychter M, Cools J, Dumez H, et al (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against Imatinib-resistant mutants. Gastroenterology 128: 270-279
35. Wardelmann E,Thomas N, Merkelbach-Bruse S (2005) Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations. Lancet Oncol 6: 249-251
36. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749
37. Prenen H, Cools J, Mentens N et al. (2006) Efficacy ofthe kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627
38. Demetri GD, Benjamin RS, Blanke CD et al (2007) management of patients with gastrointestinal stromal tumor (GIST) - update ofthe NCCN clinical practice guidelines. J Natl Compr Cane Netw 5 [suppl 2]:S1-S29;
39. quiz S30. Review. Erratum in: J Natl Compr Cane Netw 5(7)
40. Casali PG, Jost L, Reichardt P et al (2009) ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 [suppl 4]:iv64-67